RAMUCIRUMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 304 adverse event reports in the FDA FAERS database where RAMUCIRUMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for RAMUCIRUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 743 | 13.9% | 343 | 243 |
| Death | 492 | 9.2% | 492 | 51 |
| Interstitial lung disease | 269 | 5.0% | 55 | 131 |
| Febrile neutropenia | 229 | 4.3% | 70 | 148 |
| Neutropenia | 229 | 4.3% | 45 | 58 |
| Decreased appetite | 187 | 3.5% | 37 | 96 |
| Diarrhoea | 186 | 3.5% | 34 | 92 |
| Hypertension | 175 | 3.3% | 31 | 58 |
| Pyrexia | 161 | 3.0% | 27 | 107 |
| Nausea | 160 | 3.0% | 39 | 69 |
| Fatigue | 159 | 3.0% | 28 | 55 |
| Disease progression | 153 | 2.9% | 39 | 31 |
| Ascites | 152 | 2.8% | 40 | 74 |
| Neutrophil count decreased | 150 | 2.8% | 30 | 72 |
| Off label use | 148 | 2.8% | 30 | 49 |
Other Indications for RAMUCIRUMAB
Gastric cancer (1,257)
Product used for unknown indication (780)
Non-small cell lung cancer (405)
Adenocarcinoma gastric (264)
Colon cancer (222)
Gastric cancer stage iv (178)
Oesophageal adenocarcinoma (158)
Hepatocellular carcinoma (156)
Metastatic gastric cancer (156)
Gastric cancer recurrent (128)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)